Eric Hsu
Corporate Officer/Principal at INMED PHARMACEUTICALS INC.
Net worth: 19 $ as of 2024-03-30
Profile
Eric C.
Hsu is currently the Vice President-Preclinical Research & Development at InMed Pharmaceuticals, Inc. Prior to this, he worked at enGene, Inc. for 16 years as the VP-Scientific Affairs, Research & Operations.
He completed his undergraduate degree at McGill University and received his doctorate from the University of Toronto in 1999.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-03 | 51 ( 0.00% ) | 19 $ | 2024-03-30 |
Eric Hsu active positions
| Companies | Position | Start |
|---|---|---|
| INMED PHARMACEUTICALS INC. | Corporate Officer/Principal | 2018-03-12 |
Former positions of Eric Hsu
| Companies | Position | End |
|---|---|---|
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Chief Operating Officer | 2017-12-31 |
Training of Eric Hsu
| McGill University | Undergraduate Degree |
| University of Toronto | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| INMED PHARMACEUTICALS INC. | Health Technology |
| Private companies | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- Eric Hsu
